Skip to main content
Top
Published in: Respiratory Research 1/2021

Open Access 01-12-2021 | Idiopathic Pulmonary Fibrosis | Review

Educational aspects of rare and orphan lung diseases

Authors: Tiago M. Alfaro, Marlies S. Wijsenbeek, Pippa Powell, Daiana Stolz, John R. Hurst, Michael Kreuter, Catharina C. Moor

Published in: Respiratory Research | Issue 1/2021

Login to get access

Abstract

People with rare lung diseases often suffer the burden of delayed diagnosis, limited treatment options, and difficulties in finding expert physicians. One of the reasons for the delay in diagnosis is the limited training for healthcare practitioners on rare diseases. This review explores the main concerns and needs for education on rare lung diseases from the perspectives of both patients and professionals. Despite the increasing interest in rare lung disorders and some recent breakthrough developments on the management of several diseases, healthcare professionals, including general practitioners and hospital workers, receive little education on this topic. Nonetheless, many healthcare professionals show much interest in receiving further training, especially on diagnosis. Patients and families want easier access to high-quality education materials to help them manage their own disease. Well-educated patients are better equipped to deal with chronic diseases, but patient education can be challenging as patients’ individual health issues, and diverse backgrounds can create significant barriers. Raising more awareness for rare lung diseases and further development of patient-centred international expert networks like the European Reference Network on Rare Lung Diseases (ERN-LUNG), which includes both experts and patient representatives, are essential for improving care and education on rare lung diseases. Initiatives such as the Rare Disease Day, have been successful in increasing awareness for rare conditions. The development of online tools for accessing information has had positive effects and should be further supported and extended in the future.
Literature
1.
go back to reference Gupta S, Bayoumi AM, Faughnan ME. Rare lung disease research: strategies for improving identification and recruitment of research participants. Chest. 2011;140(5):1123–9.PubMedCrossRef Gupta S, Bayoumi AM, Faughnan ME. Rare lung disease research: strategies for improving identification and recruitment of research participants. Chest. 2011;140(5):1123–9.PubMedCrossRef
2.
3.
go back to reference Cordier JF. Orphan lung diseases. In: Cordier JF, editor. European Respiratory Society. 2011. 373 p. Cordier JF. Orphan lung diseases. In: Cordier JF, editor. European Respiratory Society. 2011. 373 p.
4.
go back to reference Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.PubMedCrossRef Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.PubMedCrossRef
5.
go back to reference Elliott E, Zurynski Y. Rare diseases are a ‘common’ problem for clinicians. Aust Fam Physician. 2015;44:630–3.PubMed Elliott E, Zurynski Y. Rare diseases are a ‘common’ problem for clinicians. Aust Fam Physician. 2015;44:630–3.PubMed
6.
go back to reference Harari S, Humbert M. Toward better management of rare and orphan pulmonary diseases. Eur Respir J. 2016;47(5):1334–5.PubMedCrossRef Harari S, Humbert M. Toward better management of rare and orphan pulmonary diseases. Eur Respir J. 2016;47(5):1334–5.PubMedCrossRef
10.
go back to reference Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371(9629):2039–41.PubMedCrossRef Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371(9629):2039–41.PubMedCrossRef
11.
go back to reference Domaradzki J, Walkowiak D. Medical students’ knowledge and opinions about rare diseases: a case study from Poland. Intractable Rare Dis Res. 2019;8(4):252–9.PubMedPubMedCentralCrossRef Domaradzki J, Walkowiak D. Medical students’ knowledge and opinions about rare diseases: a case study from Poland. Intractable Rare Dis Res. 2019;8(4):252–9.PubMedPubMedCentralCrossRef
12.
go back to reference Ramalle-Gomara E, Dominguez-Garrido E, Gomez-Eguilaz M, Marzo-Sola ME, Ramon-Trapero JL, Gil-de-Gomez J. Education and information needs for physicians about rare diseases in Spain. Orphanet J Rare Dis. 2020;15(1):18.PubMedPubMedCentralCrossRef Ramalle-Gomara E, Dominguez-Garrido E, Gomez-Eguilaz M, Marzo-Sola ME, Ramon-Trapero JL, Gil-de-Gomez J. Education and information needs for physicians about rare diseases in Spain. Orphanet J Rare Dis. 2020;15(1):18.PubMedPubMedCentralCrossRef
14.
go back to reference Cordier J-F, Cottin V. Orphan lung diseases from definition to organisation of care. In: Cottin V, Cordier J-F, Richeldi L, editors. Orphan lung diseases a clinical guide to rare lung disease. London: Springer; 2015. p. 1–3. Cordier J-F, Cottin V. Orphan lung diseases from definition to organisation of care. In: Cottin V, Cordier J-F, Richeldi L, editors. Orphan lung diseases a clinical guide to rare lung disease. London: Springer; 2015. p. 1–3.
15.
go back to reference Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med. 2013;1(6):479–87.PubMedCrossRef Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med. 2013;1(6):479–87.PubMedCrossRef
16.
go back to reference Kopeć G, Podolec P. Establishing a curriculum on rare diseases for medical students. J Rare Cardiovasc Dis. 2015;2(3):74–6. Kopeć G, Podolec P. Establishing a curriculum on rare diseases for medical students. J Rare Cardiovasc Dis. 2015;2(3):74–6.
17.
go back to reference Council of the European Union. Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Off J Eur Union. 2009;151:710. Council of the European Union. Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Off J Eur Union. 2009;151:710.
19.
go back to reference Humbert M, Wagner TO. Rare respiratory diseases are ready for primetime: from Rare Disease Day to the European Reference Networks. Eur Respir J. 2017;49(2):1700085.PubMedCrossRef Humbert M, Wagner TO. Rare respiratory diseases are ready for primetime: from Rare Disease Day to the European Reference Networks. Eur Respir J. 2017;49(2):1700085.PubMedCrossRef
21.
go back to reference Alfaro T, Barata F, Elphinstone M, Sutter S, Santos S, Mitchell S, et al. Greek gods and Portuguese pneumology: implementing HERMES. Rev Port Pneumol (2006). 2015;21(6):291–2. Alfaro T, Barata F, Elphinstone M, Sutter S, Santos S, Mitchell S, et al. Greek gods and Portuguese pneumology: implementing HERMES. Rev Port Pneumol (2006). 2015;21(6):291–2.
22.
go back to reference Loddenkemper R, Séverin T, Eiselé J-L, Chuchalin A, Donner CF, Di Maria G, et al. HERMES: a European core syllabus in respiratory medicine. Breathe. 2006;3(1):59–69.CrossRef Loddenkemper R, Séverin T, Eiselé J-L, Chuchalin A, Donner CF, Di Maria G, et al. HERMES: a European core syllabus in respiratory medicine. Breathe. 2006;3(1):59–69.CrossRef
23.
go back to reference Farr A, Aliberti S, Loukides S, Massard G, Primhak R, Rohde GGU, et al. A pathway to keep all lifelong learners up to date: the ERS continuing professional development programme. Eur Respir J. 2020;55(2):1902425.PubMedCrossRef Farr A, Aliberti S, Loukides S, Massard G, Primhak R, Rohde GGU, et al. A pathway to keep all lifelong learners up to date: the ERS continuing professional development programme. Eur Respir J. 2020;55(2):1902425.PubMedCrossRef
26.
go back to reference Powell P, Smyth D, Saraiva I, Lisspers K, Hardavella G, Fuertes J, et al. What do patients know? Education from the European Lung Foundation perspective. Breathe (Sheff). 2018;14(1):30–5.CrossRef Powell P, Smyth D, Saraiva I, Lisspers K, Hardavella G, Fuertes J, et al. What do patients know? Education from the European Lung Foundation perspective. Breathe (Sheff). 2018;14(1):30–5.CrossRef
30.
go back to reference Balbi B, Vallese D, Chavannes N, Stallberg B, Baiardi P. General practitioners and rare lung diseases: a task force for the development of rare lung diseases educational material. Breathe. 2016;12(4):341–8.PubMedPubMedCentralCrossRef Balbi B, Vallese D, Chavannes N, Stallberg B, Baiardi P. General practitioners and rare lung diseases: a task force for the development of rare lung diseases educational material. Breathe. 2016;12(4):341–8.PubMedPubMedCentralCrossRef
31.
go back to reference McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, et al. The importance of patient perspectives in pulmonary hypertension. Eur Respir J. 2019;53(1):1801919.PubMedPubMedCentralCrossRef McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, et al. The importance of patient perspectives in pulmonary hypertension. Eur Respir J. 2019;53(1):1801919.PubMedPubMedCentralCrossRef
32.
go back to reference Powell P, Kreuter M, Wijsenbeek-Lourens M. Where are the gaps in education in the field of rare lung disease? Perspectives from the ERN-LUNG educational programme survey. Breathe (Sheff). 2019;15(2):102–3.CrossRef Powell P, Kreuter M, Wijsenbeek-Lourens M. Where are the gaps in education in the field of rare lung disease? Perspectives from the ERN-LUNG educational programme survey. Breathe (Sheff). 2019;15(2):102–3.CrossRef
33.
go back to reference Darretxe L, Gaintza Z, Monzon-Gonzalez J. A systematic review of research into rare diseases in the educational sphere. Educ Res Rev. 2017;12(10):589–94.CrossRef Darretxe L, Gaintza Z, Monzon-Gonzalez J. A systematic review of research into rare diseases in the educational sphere. Educ Res Rev. 2017;12(10):589–94.CrossRef
34.
go back to reference Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, et al. Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers. Chron Respir Dis. 2019;16:1479973119858961.PubMedPubMedCentralCrossRef Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, et al. Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers. Chron Respir Dis. 2019;16:1479973119858961.PubMedPubMedCentralCrossRef
37.
go back to reference Cheema TJ, Young M, Rabold E, Barbieri AN, Baldwin N, Steen VD. Patient and physician perspectives on systemic sclerosis-associated interstitial lung disease. Clin Med Insights Circ Respir Pulm Med. 2020;14:1179548420913281.PubMedPubMedCentralCrossRef Cheema TJ, Young M, Rabold E, Barbieri AN, Baldwin N, Steen VD. Patient and physician perspectives on systemic sclerosis-associated interstitial lung disease. Clin Med Insights Circ Respir Pulm Med. 2020;14:1179548420913281.PubMedPubMedCentralCrossRef
38.
go back to reference Neuberger J. The educated patient: new challenges for the medical profession. J Intern Med. 2000;247(1):6–10.PubMedCrossRef Neuberger J. The educated patient: new challenges for the medical profession. J Intern Med. 2000;247(1):6–10.PubMedCrossRef
39.
go back to reference Howcroft M, Walters EH, Wood-Baker R, Walters JA. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;12:CD005074.PubMed Howcroft M, Walters EH, Wood-Baker R, Walters JA. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;12:CD005074.PubMed
41.
go back to reference Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, et al. Understanding the informational needs of patients with IPF and their caregivers: “You get diagnosed, and you ask this question right away, what does this mean?” BMJ Open Qual. 2018;7(1):e000207.PubMedPubMedCentralCrossRef Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, et al. Understanding the informational needs of patients with IPF and their caregivers: “You get diagnosed, and you ask this question right away, what does this mean?” BMJ Open Qual. 2018;7(1):e000207.PubMedPubMedCentralCrossRef
43.
go back to reference Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of sarcoidosis. Clin Chest Med. 2015;36(4):727–37.PubMedCrossRef Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of sarcoidosis. Clin Chest Med. 2015;36(4):727–37.PubMedCrossRef
44.
go back to reference Sampson C, Gill BH, Harrison NK, Nelson A, Byrne A. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med. 2015;15:155.PubMedPubMedCentralCrossRef Sampson C, Gill BH, Harrison NK, Nelson A, Byrne A. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med. 2015;15:155.PubMedPubMedCentralCrossRef
45.
go back to reference Hester KLM, Newton J, Rapley T, De Soyza A. Patient information, education and self-management in bronchiectasis: facilitating improvements to optimise health outcomes. BMC Pulm Med. 2018;18(1):80.PubMedPubMedCentralCrossRef Hester KLM, Newton J, Rapley T, De Soyza A. Patient information, education and self-management in bronchiectasis: facilitating improvements to optimise health outcomes. BMC Pulm Med. 2018;18(1):80.PubMedPubMedCentralCrossRef
46.
go back to reference Morisset J, Dube BP, Garvey C, Bourbeau J, Collard HR, Swigris JJ, et al. The unmet educational needs of patients with interstitial lung disease. Setting the stage for tailored pulmonary rehabilitation. Ann Am Thorac Soc. 2016;13(7):1026–33.PubMedPubMedCentralCrossRef Morisset J, Dube BP, Garvey C, Bourbeau J, Collard HR, Swigris JJ, et al. The unmet educational needs of patients with interstitial lung disease. Setting the stage for tailored pulmonary rehabilitation. Ann Am Thorac Soc. 2016;13(7):1026–33.PubMedPubMedCentralCrossRef
47.
go back to reference Holland AE, Fiore JF Jr, Goh N, Symons K, Dowman L, Westall G, et al. Be honest and help me prepare for the future: what people with interstitial lung disease want from education in pulmonary rehabilitation. Chron Respir Dis. 2015;12(2):93–101.PubMedCrossRef Holland AE, Fiore JF Jr, Goh N, Symons K, Dowman L, Westall G, et al. Be honest and help me prepare for the future: what people with interstitial lung disease want from education in pulmonary rehabilitation. Chron Respir Dis. 2015;12(2):93–101.PubMedCrossRef
48.
go back to reference Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment. BMC Pulm Med. 2016;16:10.PubMedPubMedCentralCrossRef Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment. BMC Pulm Med. 2016;16:10.PubMedPubMedCentralCrossRef
49.
go back to reference Fisher JH, O’Connor D, Flexman AM, Shapera S, Ryerson CJ. Accuracy and reliability of internet resources for information on idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(2):218–25.PubMedCrossRef Fisher JH, O’Connor D, Flexman AM, Shapera S, Ryerson CJ. Accuracy and reliability of internet resources for information on idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(2):218–25.PubMedCrossRef
50.
go back to reference Goobie GC, Guler SA, Johannson KA, Fisher JH, Ryerson CJ. YouTube videos as a source of misinformation on idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2019;16(5):572–9.PubMedCrossRef Goobie GC, Guler SA, Johannson KA, Fisher JH, Ryerson CJ. YouTube videos as a source of misinformation on idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2019;16(5):572–9.PubMedCrossRef
52.
go back to reference Moor CC, van Manen MJG, van Hagen PM, Miedema JR, van den Toorn LM, Gur-Demirel Y, et al. Needs, perceptions and education in sarcoidosis: a live interactive survey of patients and partners. Lung. 2018;196(5):569–75.PubMedPubMedCentralCrossRef Moor CC, van Manen MJG, van Hagen PM, Miedema JR, van den Toorn LM, Gur-Demirel Y, et al. Needs, perceptions and education in sarcoidosis: a live interactive survey of patients and partners. Lung. 2018;196(5):569–75.PubMedPubMedCentralCrossRef
53.
go back to reference Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, et al. European IPF patient charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016;47(2):597–606.PubMedCrossRef Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, et al. European IPF patient charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016;47(2):597–606.PubMedCrossRef
54.
go back to reference Braido F, Baiardini I, Sumberesi M, Canonica GW, Blasi F, Castellani C. Public awareness on cystic fibrosis: results from a national pragmatic survey. Eur Respir J. 2015;46(1):264–7.PubMedCrossRef Braido F, Baiardini I, Sumberesi M, Canonica GW, Blasi F, Castellani C. Public awareness on cystic fibrosis: results from a national pragmatic survey. Eur Respir J. 2015;46(1):264–7.PubMedCrossRef
58.
go back to reference Gates B. Responding to Covid-19—a once-in-a-century pandemic? N Engl J Med. 2020;382(18):1677–9.PubMedCrossRef Gates B. Responding to Covid-19—a once-in-a-century pandemic? N Engl J Med. 2020;382(18):1677–9.PubMedCrossRef
61.
go back to reference The impact of Covid19 for people living with a rare disease. The impact of Covid19 for people living with a rare disease.
62.
63.
go back to reference Lucey CR, Johnston SC. The transformational effects of COVID-19 on medical education. JAMA. 2020;324(11):1033–4.PubMedCrossRef Lucey CR, Johnston SC. The transformational effects of COVID-19 on medical education. JAMA. 2020;324(11):1033–4.PubMedCrossRef
64.
go back to reference Yu C, Teh BM, Aung AK. COVID-19 significantly affects specialty training. Intern Med J. 2020;50(9):1160–1.PubMedCrossRef Yu C, Teh BM, Aung AK. COVID-19 significantly affects specialty training. Intern Med J. 2020;50(9):1160–1.PubMedCrossRef
67.
go back to reference Ho RJY. Warp-speed Covid-19 vaccine development: beneficiaries of maturation in biopharmaceutical technologies and public-private partnerships. J Pharm Sci. 2020;110:615–8.PubMedPubMedCentralCrossRef Ho RJY. Warp-speed Covid-19 vaccine development: beneficiaries of maturation in biopharmaceutical technologies and public-private partnerships. J Pharm Sci. 2020;110:615–8.PubMedPubMedCentralCrossRef
68.
go back to reference Barnes PJ, Bonini S, Seeger W, Belvisi MG, Ward B, Holmes A. Barriers to new drug development in respiratory disease. Eur Respir J. 2015;45(5):1197–207.PubMedCrossRef Barnes PJ, Bonini S, Seeger W, Belvisi MG, Ward B, Holmes A. Barriers to new drug development in respiratory disease. Eur Respir J. 2015;45(5):1197–207.PubMedCrossRef
69.
go back to reference Jansen-van der Weide MC, Gaasterland CMW, Roes KCB, Pontes C, Vives R, Sancho A, et al. Rare disease registries: potential applications towards impact on development of new drug treatments. Orphanet J Rare Dis. 2018;13(1):154.PubMedPubMedCentralCrossRef Jansen-van der Weide MC, Gaasterland CMW, Roes KCB, Pontes C, Vives R, Sancho A, et al. Rare disease registries: potential applications towards impact on development of new drug treatments. Orphanet J Rare Dis. 2018;13(1):154.PubMedPubMedCentralCrossRef
Metadata
Title
Educational aspects of rare and orphan lung diseases
Authors
Tiago M. Alfaro
Marlies S. Wijsenbeek
Pippa Powell
Daiana Stolz
John R. Hurst
Michael Kreuter
Catharina C. Moor
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2021
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-021-01676-1

Other articles of this Issue 1/2021

Respiratory Research 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine